Todos Medical Announces Addition of Semi-Quantitat

Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test

·       Reauthorization of EUA expands beyond initial qualitative detection claim

·       CEO to appear on Cheddar News at 6:10pm tonight, November 17th, 2021

New York, NY, and Tel Aviv, ISRAEL, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that the United States Food & Drug Administration has reauthorized the Emergency Use Authorization (EUA) for the cPass neutralizing antibody test (“cPass”)*. The new indication for cPass now reads:

Qualitative and semi-quantitative direct detection of total neutralizing antibodies to SARS-CoV-2 in human serum and dipotassium EDTA plasma. Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Emergency use of this test is limited to authorized laboratories.

Concurrent with this announcement, the Company announced that CEO Gerald Commissiong is to appear on Cheddar News at 6:10pm tonight, November 17th, 2021.
https://investor.todosmedical.com/news-events...tive-titer